Egevad L - Search Results

1

Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.

Thysell E, Vidman L, Ylitalo EB, Jernberg E, Crnalic S, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Widmark A, Rydén P, Bergh A, Wikström P. Thysell E, et al. Among authors: egevad l. Mol Oncol. 2019 Aug;13(8):1763-1777. doi: 10.1002/1878-0261.12526. Epub 2019 Jun 27. Mol Oncol. 2019. PMID: 31162796 Free PMC article.

2

Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival.

Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Lissbrant IF, et al. Among authors: egevad l. Int J Oncol. 2000 Sep;17(3):445-51. doi: 10.3892/ijo.17.3.445. Int J Oncol. 2000. PMID: 10938382

3

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Stattin P, et al. Among authors: egevad l. J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7. doi: 10.1093/jnci/92.23.1910. J Natl Cancer Inst. 2000. PMID: 11106682

4

Prognostic value of the Gleason score in prostate cancer.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Egevad L, et al. BJU Int. 2002 Apr;89(6):538-42. doi: 10.1046/j.1464-410x.2002.02669.x. BJU Int. 2002. PMID: 11942960

5

Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.

Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Wikström P, et al. Among authors: egevad l. Prostate. 2002 Jun 1;51(4):268-75. doi: 10.1002/pros.10083. Prostate. 2002. PMID: 11987155

6

Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Egevad L, et al. J Urol. 2002 Aug;168(2):509-13. J Urol. 2002. PMID: 12131299

7

Gene expression profiling identifies clinically relevant subtypes of prostate cancer.

Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Lapointe J, et al. Among authors: egevad l. Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6. doi: 10.1073/pnas.0304146101. Epub 2004 Jan 7. Proc Natl Acad Sci U S A. 2004. PMID: 14711987 Free PMC article.

8

Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer.

Lind AJ, Wikström P, Granfors T, Egevad L, Stattin P, Bergh A. Lind AJ, et al. Among authors: egevad l. Prostate. 2005 Mar 1;62(4):394-9. doi: 10.1002/pros.20163. Prostate. 2005. PMID: 15378518

9

Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.

Josefsson A, Wikström P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A. Josefsson A, et al. Among authors: egevad l. Eur Urol. 2005 Oct;48(4):577-83. doi: 10.1016/j.eururo.2005.05.016. Eur Urol. 2005. PMID: 15990221

10

Proteomic analysis of protein expression in prostate cancer.

Lexander H, Palmberg C, Auer G, Hellström M, Franzén B, Jörnvall H, Egevad L. Lexander H, et al. Among authors: egevad l. Anal Quant Cytol Histol. 2005 Oct;27(5):263-72. Anal Quant Cytol Histol. 2005. PMID: 16447818

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

413 results

Search Page